← Research ProtocolsSemaglutide
STUDIED EXPOSURE MAP / 2025
Semaglutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 2DIABETES CARESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
2 mg
SC · once weekly
8 mg
SC · once weekly
16 mg
SC · once weekly
Context: This phase-2 study deliberately tested doses up to 16 mg/week with escalation. These are trial arms, not a public dosing schedule.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / DIABETES CARE
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2025
01 / DESIGNParallel-group · participant- and investigator-blinded · placebo-controlled phase 2
02 / POPULATION / MODEL245 adults with type 2 diabetes and BMI ≥27 kg/m² on metformin
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME40 weeks
05 / PRIMARY QUESTIONDose-dependent metabolic and weight outcomes
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.